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Letters to the EditorTHE EFFECTIVENESS OF
SIMPLIFIED FROZEN
ELEPHANT TRUNK REPAIR
FOR ACUTE DEBAKEY TYPE I
DISSECTION
To the Editor:
We read with great interest the
recently published study by Roselli
et al1 regarding the effectiveness of
simplified frozen elephant trunk repair
for acute DeBakey type I dissection.
In this clinical study, a single,
commercially available descending
thoracic stent graft was delivered an-
tegrade directly into the open de-
scending aorta. Two of the flares on
the stent graft were resected to create
a fenestration around the supra-aortic
branch vessel. The stent graft at the
base of this fenestration then was su-
tured to the base of the branch artery
with a pledgeted mattress suture. By
using such a simplified procedure,
extended repair of the ascending
aorta, arch, and upper descending
aorta were performed during the
same surgical intervention. We
congratulate them for their excellent
clinical results and also would like to
discuss a few questions regarding the
effectiveness of the simplified
procedure.
The stent graft selected for the
simplified procedure is what was
used in the intervention procedure.
In general, the proximal end of such
a stent is designed to open widely to
provide strong radial force to
strengthen the proximal fixation.2 Ac-
cording to the reported procedure, 2 of
the flares on the proximal end of the
stent graft were resected to create a
fenestration around the supra-aortic
branch vessel. The integrity of the
proximal end of the stent graft was de-
stroyed and the proximal end of the
stent graft might not attach to the
native aorta so tightly. We think that
there is a potential risk for a type 1 en-
doleak, although only a type 2 endo-
leak from the left subclavian artery
was detected in the small series during
the short follow-up period. We have
another concern regarding the broken730 The Journal of Thoracic and Cends of the metal stent after removing
2 of the flares. After the metal stent is
cut, the spring of the stent may create
strong radical force at both broken
ends and cause injury to the aortic
wall. We alsowant to know the indica-
tions for such a simplified procedure.
If the arch vessels are affected by the
dissection or the primary tear is
located at the great curvature of the
arch, can such a procedure be used?
In the reported series, the left subcla-
vian artery was covered by the stent
graft in almost half of the patients.
Although ligation of the left subcla-
vian artery after strict evaluation of
collateral circulation could be safe
for type A dissection patients,3 subcla-
vian artery steal syndrome or arm
ischemia may be inevitable in some
cases. In addition, what was the inci-
dence rate of such complications in
the patients whose left subclavian ar-
tery was sacrificed?
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We appreciate the insightful com-
ments from Drs Gu and Shi regarding
our article describing the initial
experience with a simplified single
anastomosis frozen elephant trunkardiovascular Surgery c September 201repair for acute DeBakey type I
dissection.1
They are concerned with the integ-
rity of the stent-graft after modifica-
tion. The device is made of 3
separate stents: one at each flared
end and one continuous stent
comprising the main body. Trimming
flares from one end within the arch
will not affect the rest of the device
because it is a separate stent. Bare
ends of the wire have not posed a
problem because the flares are
securely covered with graft material,
and this portion of the device is
directly sutured within the aorta. Dur-
ing this procedure, the device is fixed
to the aortic wall not only by radial
force and sutures at the base of the
branch vessel but also by at least half
of the circumference of the suture
line between the ascending surgical
graft and the aortic wall (the conven-
tional hemiarch anastomosis). Despite
no issues with the initial published
experience, we have since had a pa-
tient develop a proximal type 1 endo-
leak. Because the device was directly
sutured to the aorta, migration is not
an issue. This endoleak was easily ad-
dressed with endovascular emboliza-
tion, and we now place additional
full-thickness tacking sutures within
the arch to achieve better seal. Our
hope is that in the future there will
be a disease-specific device that al-
lows for even easier performance of
this simplified single anastomosis
technique.
The team from Shenyang also
asked about indications. This tech-
nique is applicable to a wide variety
of patients presenting with type I
dissection. In this initial series of
consecutive patients, there have been
7 entry tears extending through the
arch, a patient with aneurysmal arch,
1 descending tear extending retro-
gradely, and several patients with
dissection into the arch branches.
Tears within the arch were easily
covered by the stent-graft. The entry
tear rarely occurs right at the base of
a branch vessel. It may be necessary3
Letters to the Editorto reimplant that vessel separately, but
only if the tear cannot be repaired by
direct suturing reinforced with the
stent-graft device.
Finally, covering the left subclavian
artery was not associated with any
acute malperfusion. Admittedly, the
series is small and left subclavian mal-
perfusion can become an issue during
follow-up. Delayed revascularization
is a simple solution to this problem if
needed. Two patients have developed
type 2 endoleaks and underwent sub-
sequent carotid to subclavian bypass
with embolization at the origin.
If a disease-specific device were
available, it may be easier to preserve
the subclavian artery during this pro-
cedure. More important, approxi-
mately half of the patients presented
with malperfusion, and all were
readily managed in the hybrid oper-
ating room by this technique that opti-
mizes true lumen flow with or without
additional endovascular procedures
performed promptly enough to avoid
permanent end-organ injury.
This procedure is safe and effective,
and we will continue to use commer-
cially available stent-grafts with
modification because we believe this
operation represents an improvement
in care, especially for those patients
with malperfusion. Our hope is that a
new device, specifically designed for
this application, will become avail-
able to allow for more widespread
adoption.
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RANDOMIZED TRIALS,
NETWORK META-ANALYSES,
AND CONFLICTS OF
INTERESTS
To the Editor:
I thank Pagano and colleagues1 for
the letter on my comment2 about their
recent article on a mixed-treatment
comparisonmeta-analysis (also known
as ‘‘network meta-analysis’’) of ran-
domized trials comparing aprotinin
and other antifibrinolytics in adult
cardiac surgery.3
I am disappointed with some of the
content in their reply1 because meth-
odologic issues remained unanswered
and unclear. Also, their statements
could potentially contribute to confu-
sion. It is also disturbing if we care-
fully explore their discordant results
with a recent network meta-analysis
of both randomized and observational
evidence by Hutton and colleagues,4
wherein the authors concluded that
‘‘[a]lthough meta-analyses of ran-
domized controlled trials were largely
inconclusive, inclusion of observa-
tional data suggest concerns remain
about the safety of aprotinin. Tranexa-
mic and epsilon-aminocaproic acid
are effective alternatives that may be
safer for patients.’’
I acknowledge randomized trials
are the most rigorous way of deter-
mining whether a causal relation ex-
ists between an outcome and a given
drug. Particularly, randomized trials
have several important features:
random allocation to treatments; pa-
tients and investigators remain un-
aware of which treatment was given
until the trial is terminated; all thera-
peutic interventions are treated identi-
cally except for the experimental
drug; patients are normally analyzed
within the group to which they were
allocated (intention-to-treat analysis);
and the analyses are primary, focused
on estimating the effect size in prede-
fined outcomes. On the same line, it is
generally accepted that meta-analyses
(and more recently, network meta-
analyses) are a useful tool to criticallyof Thoracic and Cardiovascular Surgeassess the totality of clinical evidence
in a research question, but when con-
ducted in a comprehensive and trans-
parent way. It is worthy of note that
even all data in a study-level meta-
analysis came from randomized trials,
the power of randomization is
completely lost (the objects of anal-
ysis are the trials, not the patients),
and the data are reduced to the equiv-
alent of those results derived from
observational data.
It is not, however, true to say that
small-trial bias does not represent an
issue when it comes to comparative
trials; it is widely documented in the
scientific literature whether small
‘‘negative’’ trials could remain unpub-
lished indefinitely, but most impor-
tant, how the potential manipulation
in small trials (eg, selection of specific
patients, selective reporting) could
lead to more favorable effect sizes
compared with those reported in
larger randomized trials.
Finally, I have found some of the
language in the reply1 to be somewhat
unfortunately chosen. Particularly,
they wonder whether my employment
by a governmental public health
agency constitutes a declarable con-
flict of interest; in this sense, I should
declare that the opinions on my
comment2 are completely my own
and do not necessarily represent those
of any regulatory body. I acknowledge
conflicts of interests are common, but
they are a condition not a behavior,
and there is nothing wrong with hav-
ing conflict of interests. No statement
will solve the conflict of interests
problem. It is interesting to show,
however, that although the authors
technically do not breach the Jour-
nal’s formal rules regarding declara-
tion of conflicts of interest, as their
own earlier research indicates, some
of the authors have received honoraria
from aprotinin’s manufacturer.5
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